Published in Blood on June 21, 2005
Cyclin T1 overexpression induces malignant transformation and tumor growth. Cell Cycle (2010) 2.38
Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell (2012) 1.93
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood (2009) 1.83
Development of cell-cycle inhibitors for cancer therapy. Curr Oncol (2009) 1.57
Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology (2007) 1.48
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood (2008) 1.45
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood (2009) 1.42
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol (2010) 1.33
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood (2012) 1.27
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene (2010) 1.25
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia (2012) 1.24
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood (2008) 1.21
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood (2010) 1.12
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets (2010) 1.10
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res (2009) 1.08
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target. Curr Pharm Des (2012) 1.04
Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition. PLoS One (2011) 1.04
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood (2010) 1.02
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood (2008) 1.00
Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. Br J Haematol (2009) 0.99
P-TEFb- the final frontier. Cell Div (2009) 0.98
A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget (2014) 0.97
Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities. J Med Chem (2011) 0.97
Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther (2013) 0.96
Downregulation of Mcl-1 through inhibition of translation contributes to benzyl isothiocyanate-induced cell cycle arrest and apoptosis in human leukemia cells. Cell Death Dis (2013) 0.95
Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis. Cancer Biol Ther (2011) 0.94
Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol Cancer Ther (2013) 0.94
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. PLoS One (2014) 0.92
Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci (2009) 0.92
Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res (2010) 0.91
Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol (2008) 0.91
Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol (2010) 0.90
Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. Br J Pharmacol (2014) 0.90
8-Amino-adenosine inhibits multiple mechanisms of transcription. Mol Cancer Ther (2010) 0.90
Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma (2013) 0.89
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol (2013) 0.88
Personalized therapies in the cancer "omics" era. Mol Cancer (2010) 0.88
Apoptosis inducers in chronic lymphocytic leukemia. Oncotarget (2014) 0.87
Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis. BMC Cancer (2008) 0.87
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer (2012) 0.86
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. J Med Chem (2013) 0.86
Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget (2014) 0.85
Extrapolating the effect of deleterious nsSNPs in the binding adaptability of flavopiridol with CDK7 protein: a molecular dynamics approach. Hum Genomics (2013) 0.85
Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development. ISRN Oncol (2013) 0.84
Transcription inhibition as a therapeutic target for cancer. Cancers (Basel) (2011) 0.84
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Oncotarget (2015) 0.83
Limited redundancy in genes regulated by Cyclin T2 and Cyclin T1. BMC Res Notes (2011) 0.82
Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia (2014) 0.82
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J (2015) 0.82
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica (2009) 0.81
Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. PLoS One (2015) 0.80
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res (2013) 0.80
Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Semin Hematol (2015) 0.80
Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules. Invest New Drugs (2014) 0.79
Targeted treatment for chronic lymphocytic leukemia. Onco Targets Ther (2011) 0.79
Implication of transcriptional repression in compound C-induced apoptosis in cancer cells. Cell Death Dis (2013) 0.79
hLARP7 C-terminal domain contains an xRRM that binds the 3' hairpin of 7SK RNA. Nucleic Acids Res (2016) 0.79
Functional role of RNA polymerase II and P70 S6 kinase in KCl withdrawal-induced cerebellar granule neuron apoptosis. J Biol Chem (2015) 0.79
In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Invest New Drugs (2011) 0.78
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC Pharmacol Toxicol (2013) 0.78
Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex. J Mol Model (2013) 0.78
Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol. Int J Mol Med (2014) 0.76
Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor. Invest New Drugs (2010) 0.76
Effects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvae. Cell Cycle (2016) 0.75
Positive cyclin T expression as a favorable prognostic factor in treating gastric gastrointestinal stromal tumors. Mol Clin Oncol (2016) 0.75
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia. Ther Adv Hematol (2011) 0.75
Antitumor effects of flavopiridol on human uterine leiomyoma in vitro and in a xenograft model. Reprod Sci (2014) 0.75
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents. Curr Hematol Malig Rep (2016) 0.75
Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma. Oncol Lett (2015) 0.75
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacol Sin (2016) 0.75
ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities. Invest New Drugs (2011) 0.75
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem Commun (Camb) (2017) 0.75
Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice. PLoS One (2017) 0.75
Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science (1986) 15.84
AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci (1995) 14.81
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Chronic lymphocytic leukemia. N Engl J Med (2005) 9.99
Elongation by RNA polymerase II: the short and long of it. Genes Dev (2004) 9.17
PEST sequences and regulation by proteolysis. Trends Biochem Sci (1996) 8.90
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55
Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem (1996) 6.78
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem (2001) 5.36
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood (1998) 4.07
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest (2005) 3.99
mRNA decay mediated by two distinct AU-rich elements from c-fos and granulocyte-macrophage colony-stimulating factor transcripts: different deadenylation kinetics and uncoupling from translation. Mol Cell Biol (1995) 3.61
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol (2001) 3.55
A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell (1994) 3.35
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell (2004) 3.14
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem (2000) 3.13
Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur J Biochem (2003) 2.74
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood (2004) 2.39
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood (2002) 2.38
Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science (1987) 2.36
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J (1994) 2.16
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood (2000) 2.11
The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol (1995) 2.10
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res (2002) 1.99
Mcl-1. Int J Biochem Cell Biol (2005) 1.96
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol (1998) 1.80
Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene (2004) 1.67
Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene (2004) 1.53
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res (2004) 1.47
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia (2003) 1.39
Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol (2001) 1.33
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia (2004) 1.26
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol (2002) 1.17
The crystal structure of human CDK7 and its protein recognition properties. Structure (2004) 1.14
A conserved AU-rich element in the 3' untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis. FASEB J (2000) 1.12
RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res (2003) 1.09
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother (2003) 1.07
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood (2005) 1.06
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia (2000) 1.04
Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program (2002) 0.99
Molecular biology of chronic lymphocytic leukemia. Semin Oncol (1998) 0.98
Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol (2001) 0.97
Role of cyclinT/Cdk9 complex in basal and regulated transcription (review). Int J Oncol (2002) 0.97
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J (2004) 0.96
Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol (1999) 0.95
Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res (2005) 0.94
Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name? Mol Cancer Ther (2004) 0.89
bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. Leuk Res (1996) 0.89
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia (2004) 0.88
New directions in the diagnosis and treatment of chronic lymphocytic leukaemia. Drugs (2003) 0.86
Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction. Expert Rev Anticancer Ther (2002) 0.81
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol (2003) 4.56
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res (2005) 3.79
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood (2008) 3.19
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood (2002) 3.03
TRIM24 links a non-canonical histone signature to breast cancer. Nature (2010) 2.99
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 2.77
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol (2006) 2.68
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol (2012) 2.59
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood (2010) 2.48
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood (2011) 2.34
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25
Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J (2005) 2.25
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem (2003) 2.19
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood (2008) 2.18
Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood (2011) 2.09
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer (2008) 2.07
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood (2003) 2.06
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood (2004) 2.03
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol (2010) 2.02
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol (2003) 1.99
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol (2008) 1.99
Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) (2006) 1.96
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood (2014) 1.95
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood (2003) 1.94
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer (2003) 1.90
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood (2008) 1.87
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood (2008) 1.86
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood (2010) 1.82
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood (2008) 1.80
hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene (2003) 1.78
Richter syndrome: biology, incidence, and therapeutic strategies. Cancer (2005) 1.77
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol (2007) 1.76
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood (2011) 1.75
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood (2009) 1.75
Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood (2003) 1.72
K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res (2011) 1.72
H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther (2007) 1.69
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol (2003) 1.67
Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med (2006) 1.67
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol (2006) 1.67
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood (2013) 1.63
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood (2009) 1.62
Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome. Cell (2006) 1.61
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood (2004) 1.60
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma (2009) 1.59
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood (2004) 1.58
Relationship between hip and knee strength and knee valgus during a single leg squat. J Appl Biomech (2006) 1.58
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. Leuk Res (2009) 1.57
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood (2003) 1.57
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood (2007) 1.56
Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma (2006) 1.55
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol (2012) 1.54
Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med (2003) 1.52
Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet (2002) 1.52
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol (2004) 1.50
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood (2004) 1.49
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma (2012) 1.48
Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem (2011) 1.48
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol (2003) 1.47
miRNAs and their potential for use against cancer and other diseases. Future Oncol (2007) 1.47
The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases. Br J Haematol (2006) 1.46
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood (2002) 1.45
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood (2009) 1.42